COMPASS Pathways (CMPS) Q2 2024 earnings summary

Executive summary

• Advanced phase 3 COMP360 program in treatment-resistant depression, with top-line COMP005 data expected Q4 2024 and COMP006 data mid-2025; additional studies ongoing in PTSD and anorexia nervosa.

• Positive phase 2 results for COMP360 in PTSD showed sustained symptom improvement and no serious adverse events.

• Leadership expanded with appointments of Gino Santini as Chairman, Lori Englebert as Chief Commercial Officer, and Michael Gold as Chief R&D Officer in 2024.

• No therapeutic candidates approved for sale; operations funded by equity, debt, and warrant exercises.

• Cash and cash equivalents of $228.6M as of June 30, 2024, expected to fund operations into 2026.

Financial highlights

• Net loss for Q2 2024 was $38.1 million ($0.56/share), and for the first six months of 2024 was $73.3 million ($1.11/share), both up year-over-year.

• R&D expenses rose to $29.1 million in Q2 2024 and $54.0 million for the first half of 2024, driven by phase 3 trial costs and increased headcount.

• General and administrative expenses increased to $27.9M for the first half of 2024.

• Net cash used in operating activities was $55.2M for the six months ended June 30, 2024; Q2 2024 cash used in operations was $34.4M.

• Long-term debt was $29.4 million as of June 30, 2024.

Outlook and guidance

• Cash runway is expected to fund operations and capital expenditures into 2026, but future viability depends on ability to raise additional capital.

• Q3 2024 net cash used in operations expected between $32 million and $38 million; full-year 2024 projected at $110–$130 million, assuming receipt of 2023 R&D tax credit.

• Top-line data for COMP005 expected in Q4 2024 (possibly January), and COMP006 by mid-2025.

• Longer-term follow-up data (26 weeks) for COMP005 and COMP006 will be released 5–6 months after primary endpoint data.

• Research and development costs expected to increase as clinical programs progress.